SCHEMBL1471155

SCHEMBL1471155

O=C1C=C(c2ccc(Cl)cc2)C(=O)N1c1ccccc1Cl

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.51
LMNA P02545 2/20 0.51
CACNA1B Q00975 2/20 0.51
APBA1 Q02410 2/20 0.51
NPSR1 Q6W5P4 2/20 0.51
ALDH1A1 P00352 2/20 0.51
HCRTR1 O43613 1/20 0.51
S1PR4 O95977 1/20 0.51
HSP90AA1 P07900 1/20 0.51
HPGD P15428 1/20 0.51
ALOX12 P18054 1/20 0.51
S1PR1 P21453 1/20 0.51
MGLL Q99685 1/20 0.50
TDP1 Q9NUW8 1/20 0.43
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
CNR1 P21554 7/20 0.39
CNR2 P34972 2/20 0.39
POLB P06746 1/20 0.38
ALOX15 P16050 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1471696 0.90 MGLL (0.53) MAPTLMNACACNA1BAPBA1NPSR1
SCHEMBL1471057 0.88 RGS4 (0.52) MAPTLMNACACNA1BAPBA1NPSR1
SCHEMBL1471424 0.85 LMNA (0.45) MAPTLMNACACNA1BAPBA1NPSR1
SCHEMBL1471818 0.85 MAPT (0.49) MAPTLMNACACNA1BAPBA1NPSR1
SCHEMBL1471682 0.81 MGLL (0.51) MAPTLMNACACNA1BAPBA1NPSR1
SCHEMBL1473349 0.81 MAPT (0.57) MAPTLMNACACNA1BAPBA1NPSR1
SCHEMBL1473625 0.80 MAPT (0.45) MAPTLMNACACNA1BAPBA1NPSR1
SCHEMBL1471314 0.78 MEN1 (0.54) MAPTLMNACACNA1BAPBA1NPSR1
SCHEMBL1471657 0.78 MAPT (0.54) MAPTLMNACACNA1BAPBA1NPSR1
SCHEMBL1471117 0.75 MGLL (0.53) MAPTLMNACACNA1BAPBA1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7915304-B2 Phenyl substituted maleimides as medicaments for blocking degenerative tissue damages by inhibiting MPT CONGENIA S.R.L. (IT) 2011-03-29 US disclosed
US-20100099736-A1 PHENYL SUBSTITUTED MALEIMIDES AS MEDICAMENTS FOR BLOCKING DEGENERATIVE TISSUE DAMAGES BY INHIBITING MPT CONGENIA S.R.L. (IT) 2010-04-22 US disclosed
EP-2091531-A2 PHENYL SUBSTITUTED MALEIMIDES AS MEDICAMENTS FOR BLOCKING DEGENERATIVE TISSUE DAMAGES BY INHIBITING MPT Congenia S.r.l. (IT) 2009-08-26 EP disclosed
WO-2008067863-A2 PHENYL SUBSTITUTED MALEIMIDES AS MEDICAMENTS FOR BLOCKING DEGENERATIVE TISSUE DAMAGES BY INHIBITING MPT CONGENIA S.R.L. (IT) 2008-06-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100099736-A1 PHENYL SUBSTITUTED MALEIMIDES AS MEDICAMENTS FOR BLOCKING DEGENERATIVE TISSUE DAMAGES BY INHIBITING MPT CYC1, MTPN, TXN2 MAPT 1947/4885LMNA 1640/4885CACNA1B 2876/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.